Arcus Biosciences, Inc. financial data

Symbol
RCUS on NYSE
Location
Hayward, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 25 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 443% % -12%
Return On Equity -66% % -39%
Return On Assets -32% % -40%
Operating Margin -156% % -22%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 125,349,476 shares 18%
Common Stock, Shares, Outstanding 125,300,000 shares 36%
Entity Public Float $565,882,788 USD -31%
Weighted Average Number of Shares Outstanding, Basic 107,400,000 shares 19%
Weighted Average Number of Shares Outstanding, Diluted 107,400,000 shares 19%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $247,000,000 USD -4.3%
Revenue from Contract with Customer, Excluding Assessed Tax $33,000,000 USD -35%
Research and Development Expense $523,000,000 USD 17%
General and Administrative Expense $110,000,000 USD -8.3%
Operating Income (Loss) $386,000,000 USD -17%
Nonoperating Income (Expense) $33,000,000 USD -31%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $353,000,000 USD -25%
Income Tax Expense (Benefit) $0 USD -100%
Net Income (Loss) Attributable to Parent $353,000,000 USD -25%
Earnings Per Share, Basic -3.29 USD/shares -4.8%
Earnings Per Share, Diluted -3.29 USD/shares -4.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $222,000,000 USD 48%
Assets, Current $1,007,000,000 USD -0.89%
Property, Plant and Equipment, Net $40,000,000 USD -15%
Operating Lease, Right-of-Use Asset $58,000,000 USD -11%
Other Assets, Noncurrent $63,000,000 USD -14%
Assets $1,139,000,000 USD -0.96%
Accounts Payable, Current $42,000,000 USD 133%
Employee-related Liabilities, Current $33,000,000 USD 6.5%
Contract with Customer, Liability, Current $35,000,000 USD -59%
Liabilities, Current $231,000,000 USD 2.2%
Contract with Customer, Liability, Noncurrent $43,000,000 USD -82%
Operating Lease, Liability, Noncurrent $86,000,000 USD -13%
Other Liabilities, Noncurrent $135,000,000 USD -14%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,000,000 USD
Retained Earnings (Accumulated Deficit) $1,485,000,000 USD -31%
Stockholders' Equity Attributable to Parent $631,000,000 USD 30%
Liabilities and Equity $1,139,000,000 USD -0.96%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $132,000,000 USD -6500%
Net Cash Provided by (Used in) Financing Activities $142,000,000 USD -38%
Net Cash Provided by (Used in) Investing Activities $32,000,000 USD
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 125,300,000 shares 36%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $42,000,000 USD -28%
Deferred Tax Assets, Valuation Allowance $412,000,000 USD 30%
Deferred Tax Assets, Gross $425,000,000 USD 29%
Operating Lease, Liability $99,000,000 USD -11%
Payments to Acquire Property, Plant, and Equipment $1,000,000 USD -75%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $353,000,000 USD -25%
Lessee, Operating Lease, Liability, to be Paid $116,000,000 USD -13%
Property, Plant and Equipment, Gross $90,000,000 USD 2.3%
Operating Lease, Liability, Current $13,000,000 USD 8.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two $18,000,000 USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One $18,000,000 USD 5.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.052 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $17,000,000 USD -23%
Lessee, Operating Lease, Liability, to be Paid, Year Three $19,000,000 USD 5.6%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $24,000,000 USD 26%
Lessee, Operating Lease, Liability, to be Paid, Year Four $19,000,000 USD 0%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $60,000,000 USD -21%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%